Silk Road Medical: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Silk Road Medical (NASDAQ:SILK) reported Q4 earnings with an EPS of $-0.33, beating estimates by 21.0% against an expected $-0.42. Revenue increased by $7.20 million from the same period last year. Despite beating EPS estimates last quarter, SILK's share price dropped by 11.0% the following day. Historical earnings performance shows mixed results with both beats and misses on EPS and revenue estimates.
February 28, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Silk Road Medical reported better than expected Q4 earnings with a 21.0% beat on EPS estimates and a significant year-over-year revenue increase. However, past performance indicates a potential volatility in share price following earnings announcements.
While Silk Road Medical's Q4 earnings beat and revenue increase are positive, historical data shows that even when beating estimates, SILK's share price can experience significant volatility the following day. Given this pattern, the short-term impact on SILK's stock price is uncertain, hence a neutral score is assigned.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100